Clopidogrel and Proton Pump Inhibitors

• Published in: JACC. Cardiovascular interventions Vol. 4; no. 4; pp. 365 - 380
• Main Authors: Tantry, Udaya S., Kereiakes, Dean J., Gurbel, Paul A.
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01.04.2011
• Subjects: bleeding; Cardiovascular; clopidogrel; cytochromes; drug-drug interactions; omeprazole; platelet reactivity; proton pump inhibitors; single nucleotide polymorphisms; clopidogrel; GIB; omeprazole; FDA; GI; bleeding; CL-AM; ATPase; PPI; platelet reactivity; HPR; ADP; cytochromes; proton pump inhibitors; drug-drug interactions; MACE; MD; PCI; LD; SNPs; VASP-PRI; single nucleotide polymorphisms; MI; DAPT; maintenance dose; single nucleotide polymorphism; myocardial infarction; high on-treatment platelet reactivity; vasodilator stimulated phosphoprotein–platelet reactivity index; adenosine triphosphatase; dual antiplatelet therapy; percutaneous coronary intervention; adenosine diphosphate; clopidogrel active metabolite; U.S. Food and Drug Administration; loading dose; major adverse cardiac event(s); gastrointestinal bleeding; gastrointestinal

Dual antiplatelet therapy with aspirin and clopidogrel is associated with a significant reduction in vascular ischemic events; however, gastrointestinal bleeding events are a major concern in high-risk and older patients. Clinical practice guidelines recommend combination therapy with proton pump in...